Introduction {#s1}
============

Mitochondria are involved in a wide range of fundamental cellular processes, including cellular energy production, thermogenesis, lipid biosynthesis and cell death, and mutations in both nuclear and mitochondrial DNA (mtDNA) encoded genes have been linked to an array of different diseases ([@bib58]; [@bib21]; [@bib44]; [@bib28]; [@bib29]). Most of the genes encoded in the mitochondrial genome are transcribed as one strand of RNA, and post-transcriptional processes are therefore particularly important for gene regulation. After transcription, poly-cistronic mitochondrial RNA is processed under the 'punctuation model' whereby transfer RNAs (tRNAs) that intersperse protein-coding regions are recognized for cleavage and the release of gene products ([@bib45]; [@bib53]). Various processes including RNA modifications ([@bib22]; [@bib23]; [@bib2]), further cleavage events ([@bib40]; [@bib50]), RNA degradation ([@bib54]; [@bib49]) and translation rates then ultimately determine the levels of mitochondrial proteins available for utilization in the electron transport chain. Across tissues, different cell types have specific physiological requirements and thus variable energy demands. In mammals it has been shown that mitochondrial DNA replication ([@bib24]) and segregation ([@bib32]), mitochondrial DNA copy number ([@bib59]) and the abundance of nuclear-encoded mitochondrial proteins ([@bib41]) vary across cell types, perhaps as a way to match local energy requirements, however it is unclear whether regulation of the mitochondrial transcriptome varies across tissues. Understanding these processes is important, since many mitochondrial disorders are thought to be tissue specific ([@bib35]; [@bib20]).

Although the mitochondrial genome is transcribed, processed and translated within the mitochondria, almost all of the proteins required for these processes are coded for in the nuclear genome. Previous work has shown that the expression of a large number nuclear genes correlates with mitochondrial encoded gene expression ([@bib40]; [@bib5]), pointing to strong links between the two genomes, yet there is still not a complete understanding of which nuclear genes are directly involved in regulating the mitochondrial genome and how this might vary in different tissues, as well as whether nuclear genetic variation drives variation in these processes across individuals. Despite the wide-ranging impact of mitochondrial dysfunction on health and disease, to our knowledge only a single mitochondria-focussed study has been carried out comparing nuclear genome-wide genetic variation with mitochondrial encoded gene expression, which analysed two sets of \~70 samples and was underpowered to detect genetic variation acting across two genomes ([@bib60]). More recently, studies have shown links between mitochondrial genome mutations and nuclear gene expression, identifying 11 significant associations ([@bib33]), as well as associations between single nucleotide polymorphisms (SNPs) in mitochondrial RNA-binding proteins and haplogroup-specific mtDNA encoded gene expression patterns in LCLs ([@bib10]), providing good evidence for regulatory links between the two genomes. In general, genetic variation associated with the expression of distal genes (*trans* expression quantitative trait loci (eQTLs)) has been more difficult to find due to the large statistical burden when comparing large numbers of variants and genes, and very few significant associations have been replicated in independent datasets ([@bib30]; [@bib34]; [@bib19]).

Here we aim to characterize variation in mitochondrial encoded gene expression across \>11,000 RNA sequencing libraries for 36 different tissue/cell types. We also aim to identify genetic links between the mitochondrial and nuclear genomes through the detection of *trans*-genome eQTLs, not only to evidence occasions where genetic mechanisms act at long range across different genetic regions, but also to identify novel genes and genetic variation in the nuclear genome that are associated with fundamental processes taking place in human mitochondria.

Results {#s2}
=======

To characterize levels of mitochondrial encoded RNA across a large number of individuals and tissues, we obtained raw RNA sequencing data for 13,261 samples from five independent sequencing projects, covering 36 different tissue/cell types, including multiple independent datasets obtained from whole blood, subcutaneous adipose, skin (not sun exposed) and lymphoblastic cell lines (LCLs). For each dataset, sequencing data were processed consistently using the same stringent mapping and filtering pipeline (see Materials and methods), removing poor quality samples at each stage, leaving a total of 11,371 high quality samples for comparison ([Figure 1A](#fig1){ref-type="fig"}), allowing us to focus on biological rather than technical variation. Following this, expression levels were quantified as the number of transcripts per million reads (TPM) per sample for 13 protein-coding genes and two ribosomal RNAs encoded in the mitochondrial genome.

![Variation in the expression of mitochondrial-encoded genes across datasets.\
(**A**) Hierarchical clustering of median expression levels per gene across all datasets where WBL = Whole Blood, SAD = Subcutaneous Adipose, LCL = Lymphoblastoid cell lines, SKN = Non sun exposed skin, SKE = Sun exposed skin, VAD = Visceral omentum adipose, ADG = Adrenal gland, AOR = Aorta, CAR = Coronary artery, TAR = Tibial artery, ACB = Anterior cingulate cortex (BA24) (Brain), CGB = Caudate basal ganglia (Brain), CHB = Cerebellar Hemisphere (Brain), CEB = Cerebellum (Brain), COB = Cortex (Brain), FCB = Frontal cortex (BA9) (Brain), HIB = Hippocampus (Brain), HYB = Hypothalamus (Brain), NAB = Nucleus accumbens (basal ganglia) (Brain), PBB = Putamen basal ganglia (Brain), BRE = Breast mammary tissue, SCO = Sigmoid colon, TCO = Transverse colon, GEJ = Gastroesophageal junction, EMC = Esophagus mucosa, EMS = Esophagus Muscularis, AAH = Atrial appendage (Heart), LVH = Left ventricle (Heart), LUN = Lung, SMU = Skeletal muscle, TNV = Tibial Nerve, PAN = Pancreas, SFI = Transformed fibroblasts, STO = Stomach, TES = Testes and THY = Thyroid, Multi-dataset tissues on the x-axis are shown in red (whole blood), orange (subcutaneous adipose), green (lymphoblastoid cell lines) and blue (non-sun exposed skin). (**B**) Standardized expression levels of each mitochondrial-encoded gene across all independent datasets, (**C**) Coefficient of variation across individuals for the expression levels of mitochondrial encoded genes and the top 1000 most highly expressed nuclear genes in all datasets. Range of coefficient of variation is restricted to between 0 and 1.5 as this contains the majority of the data.](elife-41927-fig1){#fig1}

Variation in mitochondrial gene expression {#s2-1}
------------------------------------------

Overall, despite their polycistronic origins, there is significant variation between mean expression levels of the 15 mitochondria-encoded genes within each dataset (one-way ANOVA, p\<2e-16 in all cases), highlighting the influence of post-transcriptional events in generating variation in transcript abundance along the mitochondrial transcriptome in all tissues. On average across samples and datasets, *MTCO3* and *MTCO2* show the highest median expression levels and *MTRNR1* the lowest. Hierarchical clustering of log median expression values per dataset shows the consistency of the data, as the same tissue types from independent sequencing datasets generally tend to cluster together ([Figure 1A](#fig1){ref-type="fig"}). Whole blood, LCL and skin datasets group by tissue type, however subcutaneous adipose data do not; this may be a consequence of the large heterogeneity in cell type composition observed across these datasets ([@bib18]). High-energy tissues (for example heart and brain tissues) also tend to cluster together and appear to show similar patterns of mitochondrial encoded gene expression.

In general, the rank order of mitochondrial-encoded gene expression levels between tissues is broadly similar (spearman rank rho \>0.5 for 894/903 pairwise comparisons of independent datasets) with genes that show high relative expression levels in one tissue tending to show high relative expression levels in others tissues, however there are gene specific patterns. Standardized median *MTRNR2* expression levels are highly variable, showing higher relative expression in whole blood and sub regions of the brain compared to other tissue types, whereas *MTND4L*, *MTND5* and *MTATP8* have low variance across tissue types and show relatively low standardized expression ([Figure 1B](#fig1){ref-type="fig"}). Across individuals within each tissue, mitochondria-encoded genes show similar variance to comparable nuclear genes; on average across genes and datasets, the coefficient of variation of mitochondrial encoded TPM values is higher than 443 of the top 1000 most highly expressed nuclear genes and distributions of coefficients of variation overlap ([Figure 1C](#fig1){ref-type="fig"}). However, there are differences across tissues; mitochondrial encoded genes in sub-regions of the brain generally show low variation in gene expression across individuals, and expression variance in whole blood is generally high. Collectively these results point to significant variation in the expression of genes along the mitochondrial genome, across tissues and across individuals.

Nuclear control of mitochondrial gene expression {#s2-2}
------------------------------------------------

To identify nuclear genetic variation associated with mitochondrial encoded transcript abundance, we obtained genotyping data for the same samples for which we had RNA sequencing data and then performed per tissue and dataset association analyses between nuclear genetic variants (with MAF \>5%) and the expression levels of fifteen mitochondrial encoded genes within a linear model, controlling for ancestry, sex, batch (where applicable) and probabilistic estimation of expression residuals (PEER factors) ([@bib57]) obtained from RNA sequencing data. For whole blood, subcutaneous adipose, non-sun exposed skin and LCLs where we had multiple independent datasets, we defined discovery and replication datasets.

Across all tissues, we identify a total of 64 *trans*-genome eQTLs (unique peak genetic variant-gene expression pairs) for mitochondrial encoded gene expression at FDR 5% (range of FDR corrected p-values: 0.046 -- 8 × 10^−26^, [Supplementary file 1](#supp1){ref-type="supplementary-material"}, example association shown in [Figure 2A and C](#fig2){ref-type="fig"}). For each significant association, we also calculate point-wise empirical P-values (as well as gene-level and tissue-level family-wise error rates) via permutation analysis, and find that these closely match raw P-values (see Materials and methods and [supplementary file 1](#supp1){ref-type="supplementary-material"}). In total, fourteen out of the fifteen mitochondrial encoded genes have at least one nuclear genetic variant associated with its expression; *MTATP8* shows no significant associations, *MTND1* has the most with seven independent associations. We also observe five instances where a peak nuclear variant is associated with the expression of multiple mitochondrial-encoded genes within a tissue, perhaps indicating a shared influence on mitochondria RNA processing. However, mitochondrial encoded genes associated with the same genetic variant are no more likely to be located closer to each other along the mitochondrial genome than random (p=0.29, bootstrapping versus same number of random chosen genes). For the 49 unique peak genetic variants remaining after removing duplicate variants with multiple associations, four are missense mutations, 32 intronic, 12 intergenic and one falls in a 3' UTR region.

![Associations between the expression of MTND1 and rs2304694 in whole blood data.\
(**A**) Genome-wide association analysis for the expression of *MTND1* in whole blood data from the discovery datasets (meta-analysis of CARTaGENE, TwinsUK and GTEx data), (**B**) Genome-wide association analysis for the expression of *MTND1* in whole blood data from the replication dataset (NIMH data), (**C**) Expression of *MTND1* (Log~10~(TPM +1)) versus non-reference allele frequency of rs2304694 in the four independent whole blood datasets.](elife-41927-fig2){#fig2}

To ensure that *trans*-genome eQTLs are not driven by alignment errors that are a consequence of sequence similarity between the nuclear and the mitochondrial genomes, we tested for the presence of nuclear mitochondrial DNA segments (NUMTs) in the regions surrounding each peak nuclear genetic variant. NUMTs are mitochondrial DNA sequences that have transposed into the nuclear genome over evolutionary time scales, and as such often retain moderate to high sequence similarity with the mitochondrial genome. For the 64 trans-genome eQTLs, we find only two occurrences where at least 50 bp (the smallest read length in our analysis) of the mitochondrial encoded gene is present within a NUMT that is within 1 MB of the corresponding peak nuclear genetic variant, and we observe \~4 and\~15 mismatches per 100 bp in these sequences compared to the corresponding mitochondrial encoded sequence. Additionally, for each peak nuclear genetic variant that is associated with the expression of a mitochondrial-encoded gene, we also tested whether any 50 bp segment of the mitochondrial-encoded gene also mapped to a nuclear gene (following the approach defined in [@bib52]) that has its transcription start site within 1 MB of the corresponding peak nuclear variant; we find no such occurrences. As such, alignment errors are unlikely to be driving the detection of *trans*-genome eQTLs for mitochondrial encoded gene expression.

RNA levels of mitochondrial-encoded genes are likely driven by a number of features including mitochondrial copy number, polycistronic transcription rates and post-transcriptional events. Although all of these processes are important in a biological context, after detecting initial associations we focussed on the effects of post-transcriptional processing in driving variation in mitochondrial encoded gene expression. To do this, we controlled for variable mitochondrial copy number and polycistronic transcription rate by recalculating TPM values for each mitochondrial gene and sample using the number of mitochondrial reads rather than the total RNA sequencing library size. Repeating association analyses as before, 63/64 associations remain significant at FDR 5% ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Since mitochondrial encoded gene expression values are represented as a proportion of the total reads mapping to the mitochondrial genome in this analysis, this suggests that post-transcriptional processes play a significant role in these associations.

To identify whether genetic associations are tissue specific, for the 64 significant associations we tested whether the same peak variant-gene pair was significant with the same direction of effect in each of the other tissue types (at p\<0.05, corrected for the number of variants and the number of tissues, we used the nearest variant in LD (r^2^ \>0.8) if the same variant was not present, or the nearest variant with r^2^ \>0.5 otherwise). In total, 22 of the 64 associations are significant in more than one tissue, with 8 of the associations being observed in at least three other tissue types ([Supplementary file 3](#supp3){ref-type="supplementary-material"}, [Supplementary file 6](#supp6){ref-type="supplementary-material"}). Lowering the p-value threshold to 5% with the same direction of effect, only 12 associations are not replicated outside of the tissue they were originally detected in, and 19 associations are significant across 10 or more tissue types. Although sample sizes and detection criteria may influence our ability to detect all associations, these results indicate that a large number of associations between the nuclear and mitochondrial genomes may be operating via general mechanisms that occur across multiple tissue types.

Functional characterization {#s2-3}
---------------------------

In order to elucidate the potential biological mechanisms influencing mitochondrial processes, we attempted to identify the nuclear gene of action through which each nuclear genetic variant is associated with mitochondrial encoded gene expression. For missense variants, we assume a direct influence on the gene in which they are located and thus identify three nuclear genes associated with mitochondrial encoded gene expression ([Table 1](#table1){ref-type="table"}), all of which have a known role in mitochondrial processes. *TBRG4* localizes to the mitochondria to modulate energy balance (particularly under stress) and plays a role in processing mitochondrial RNA ([@bib7]), *MTPAP* synthesizes the 3\' poly(A) tail of mitochondrial transcripts, and *LONP1* mediates the degradation of mis-folded or damaged polypeptides in the mitochondrial matrix. There is evidence that all three proteins are targeted to the mitochondria, and mass spectrometry experiments have identified the presence of these proteins in mitochondria ([@bib56]).

10.7554/eLife.41927.006

###### Associations where a suggestive causal nuclear gene is implicated.

'Missense mutation' denotes that the nuclear genetic variant associated with the expression of a mitochondrial-encoded gene is a missense mutation, 'Mediation (Mitochondrial Gene)' denotes that the expression of a nearby nuclear gene known to play a role in mitochondrial processes explains a significant proportion of the association between a nuclear genetic variant and the expression level of a mitochondrial encoded gene, and 'Mediation (other nuclear gene)' denotes a similar result whereby the nuclear gene identified is thought to have no known role in mitochondrial processes (see Materials and methods).

  Tissue                   Peak SNP      MT gene    Missense mutation   Mediation (Mitochondrial Gene)   Mediation (other nuclear gene)
  ------------------------ ------------- ---------- ------------------- -------------------------------- --------------------------------
  Whole Blood              rs7558127     *MTND6*    NA                  *PNPT1*                          NA
  Whole Blood              rs6973982     *MTCO2*    NA                  *TBRG4*                          NA
  Whole Blood              rs11085147    *MTCO2*    *LONP1*             NA                               NA
  Whole Blood              rs2304693     *MTCYB*    *TBRG4*             NA                               NA
  Whole Blood              rs74025341    *MTCYB*    NA                  NA                               *SLC7A6OS,ZFP90*
  Whole Blood              rs7158706     *MTND2*    NA                  NA                               *PPP2R3C*
  Whole Blood              rs10172506    *MTND5*    NA                  *PNPT1*                          NA
  Whole Blood              rs74863981    *MTCO1*    NA                  NA                               *UBOX5,TGM3,LZTS3*
  Whole Blood              rs76125482    *MTND3*    NA                  *FASTKD1*                        NA
  Whole Blood              rs6973982     *MTND4*    NA                  NA                               *RP4-647J21.1,CCM2*
  Whole Blood              rs11008009    *MTND4*    NA                  *MTPAP*                          NA
  Whole Blood              rs2304694     *MTND1*    *TBRG4*             NA                               NA
  Whole Blood              rs1692120     *MTND1*    NA                  NA                               *MYRF*
  Whole Blood              rs6973982     *MTATP6*   NA                  NA                               *CCM2*
  Whole Blood              rs589809      *MTATP6*   NA                  NA                               *FLT1*
  Whole Blood              rs375640557   *MTCO3*    NA                  NA                               *CCDC104*
  Whole Blood              rs6973982     *MTCO3*    NA                  *TBRG4*                          NA
  Whole Blood              rs10165864    *MTRNR2*   NA                  *PNPT1*                          NA
  Whole Blood              rs66892251    *MTRNR2*   NA                  *MTPAP*                          NA
  Whole Blood              rs61988269    *MTRNR1*   NA                  *MRPP3*                          NA
  Subcutaneous Adipose     rs2304694     *MTND6*    *TBRG4*             NA                               NA
  Subcutaneous Adipose     rs2304694     *MTND5*    *TBRG4*             NA                               NA
  Subcutaneous Adipose     rs2304694     *MTND1*    *TBRG4*             NA                               NA
  Subcutaneous Adipose     rs12579998    *MTND1*    NA                  *MRPS35*                         NA
  Subcutaneous Adipose     rs2304693     *MTCO3*    *TBRG4*             NA                               NA
  Skin (Not sun exposed)   rs2304693     *MTCO2*    *TBRG4*             NA                               NA
  Skin (Not sun exposed)   rs2304693     *MTCO3*    *TBRG4*             NA                               NA
  LCLs                     rs7559561     *MTCO2*    NA                  *LRPPRC*                         NA
  LCLs                     rs2304694     *MTCO2*    *TBRG4*             NA                               NA
  LCLs                     rs1047991     *MTND3*    *MTPAP*             NA                               NA
  LCLs                     rs2304694     *MTND4*    *TBRG4*             NA                               NA
  LCLs                     rs10205130    *MTND1*    NA                  *LRPPRC*                         NA
  LCLs                     rs35739334    *MTND1*    NA                  *TBRG4*                          NA
  LCLs                     rs2304694     *MTCO3*    *TBRG4*             NA                               NA
  LCLs                     rs2304694     *MTRNR2*   *TBRG4*             NA                               NA
  LCLs                     rs2304694     *MTND4L*   *TBRG4*             NA                               NA

For genetic variants in non-coding regions (from 49 unique associations), we first annotated variants using chromatin state predictions obtained from 128 cell types within the Roadmap Epigenetic project ([@bib37]). Using tissue matched data (information available for 44 of the 49 non-coding variants), we find that none of the nuclear genetic variants associated with mitochondrial encoded gene expression fall in enhancer regions, which is not different to that expected by chance (p=0.676 using randomly selected variants matched for MAF, distance to nearest transcription start site and annotation). Under the assumption that associations between nuclear genetic variants and mitochondrial encoded gene expression occur ubiquitously across the body, we tested for the presence of peak variants in enhancer regions in any cell type. In total, 24 variants fall in enhancer regions, which again is not significantly different from that expected by chance (p=0.691, using randomly selected variants as before).

To test more directly if each nuclear non-coding genetic variant potentially acts upon mitochondrial-encoded gene expression through a nearby nuclear gene, we perform mediation analysis (requiring an association between the peak nuclear genetic variant and the expression of a nearby nuclear-encoded gene, and then significant mediation of the initial association via bootstrapping, requiring an average causal mediation effect with p\<0.05 after FDR correction). Considering only nuclear genes known to play a role in mitochondrial processes first, we identify seven genes whose expression accounts for a significant component of the relationship between the nearby nuclear genetic variant and the expression of the associated mitochondrial-encoded gene ([Table 1](#table1){ref-type="table"}). These include *TBRG4* and *MTPAP* (described above), as well as *MRPP3*, which is known to form part of a complex that cleaves and processes the 5' end of mitochondrial transfer RNAs ([@bib26]); *LRPPRC*, which is thought to play a role in the stability and transcriptional regulation of mitochondrial RNA ([@bib62]); *MRPS35*, which is a mitochondrial ribosomal protein; *PNPT1*, which is an RNA binding protein that plays a role in numerous RNA metabolic processes and the import of RNA into the mitochondria; and *FASTKD1*, which is an RNA binding protein that regulates the energy balance of mitochondria under stress. Five out of the seven proteins (*PNPT1*, *TBRG4*, *MTPAP*, *MRPP3* and *LRPPRC*) contain RNA binding domains ([@bib61]), and as such it is possible that they bind directly to mitochondrial RNA.

For the remaining non-coding peak genetic variants (from 36 unique associations), we tested whether any nearby nuclear genes (not yet implicated in mitochondrial processes) significantly mediated the expression of a mitochondria-encoded gene (as above). Using this approach, we identify eleven candidate genes that may play a previously unknown role in influencing mitochondrial gene expression ([Table 1](#table1){ref-type="table"}). In general, these genes are not predicted to contain mitochondria targeting sequences, although *SLC7A6OS* and *TGM3* show partial evidence of being targeted to mitochondria in some databases (*SLC7A6OS* prediction score of 1 in IPSort and both genes have a score \>0.6 in TargetP ([@bib56])).

Finally, to test whether peak genetic variants may be acting on mitochondrial encoded gene expression via distal associations with genes in the nuclear genome, we performed association analyses between each peak genetic variant and all other nuclear genes not in cis (genes \> 1 MB away or on different chromosomes). After correcting for multiple tests, we observe no significant associations (p\>0.05 in all cases, Bonferroni correction). Collectively these results suggest that the common mechanisms by which nuclear genetic variation influences mitochondrial encoded gene expression could be either through functional mutations within nuclear genes themselves, or via their effects on the expression of nearby nuclear genes. There is also some evidence that the protein products of some of these genes then enter the mitochondria and bind directly to mitochondrial RNA. Genes identified via these approaches therefore represent the most promising candidates for causal nuclear genes that influence fundamental biological processes taking place in human mitochondria.

Replication and validation of associations {#s2-4}
------------------------------------------

In order to test the robustness of associations between common nuclear genetic variants and mitochondrial gene expression, we tested whether *trans*-genome eQTLs detected in multi-dataset tissues were significant in independent tissue-matched samples (see Materials and methods). In total, 61 eQTLs were found in multi-dataset tissues; to consider the signal replicated we required the association to be between the same variant (or nearest variant in LD (r^2^ \>0.8) if the same variant was not present, or the nearest variant with r^2^ \>0.5 otherwise) and mitochondrial gene in the same tissue type, with the same direction of effect and passing a significance threshold corrected for the number of tests (0.05/61 = 0.00082 in this case). In total we replicate 13/61 (\~21.3%) of the mitochondrial *trans*-genome eQTLs ([Figure 3A](#fig3){ref-type="fig"}, example association shown in [Figure 2B and C](#fig2){ref-type="fig"}, [Table 2](#table2){ref-type="table"}), and for ten of these we find a link to a potential casual gene through mediation by a nearby nuclear gene or via functional mutations as outlined above ([Table 1](#table1){ref-type="table"}). We also find that an additional 12 associations replicate at the 5% level, and in total 43/61 of the associations show the same direction of effect in replication datasets; larger sample sizes may increase replication rates in these cases.

![Replication and validation of significant associations between nuclear genetic variants and the expression of mitochondria-encoded genes.\
(**A**) Discovery versus replication beta estimates for significant associations between nuclear genetic variation and mitochondrial gene expression detected in discovery data at FDR 5%, (**B**) Validation of the association between rs2304694 and the expression of *MTND4* using quantitative PCR in LCLs. *MTND4* mRNA expression levels are normalised to GAPDH (theoretical quantities).](elife-41927-fig3){#fig3}
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###### Significant associations between nuclear genetic variants and the expression levels of genes encoded in the mitochondrial genome that replicate in independent tissue matched datasets.

Point-wise permutation P values were generated by extrapolating from the underlying beta distribution (see Materials and methods).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tissue          Peak\        Chr   Position   A1   MAF     MT\      P\         P value\     P value\       Beta     Replication P value   Replication\   Nuclear gene\   Nuclear SNP\
                  nuclear\                                   gene     value      (FDR\        (Point-wise\                                  beta           annotation      annotation
                  SNP                                                            corrected)   Permutation)                                                                 
  --------------- ------------ ----- ---------- ---- ------- -------- ---------- ------------ -------------- -------- --------------------- -------------- --------------- --------------
  LCLs            rs10205130   2     44151572   C    0.426   MTND1    1.23E-10   6.40E-05     1.18E-10       0.023    5.70E-05              0.015          LRPPRC          Intronic

  Whole\          rs10172506   2     55865469   C    0.062   MTND5    4.40E-40   2.00E-33     1.39E-39       0.058    2.00E-08              0.037          PNPT1           Intronic
  Blood                                                                                                                                                                    

  Whole\          rs7558127    2     55866605   G    0.064   MTND6    5.26E-32   8.30E-26     5.29E-32       0.070    8.70E-07              0.043          PNPT1           Intronic
  Blood                                                                                                                                                                    

  LCLs            rs2627775    2     55877113   T    0.458   MTCO1    1.33E-09   4.10E-04     9.95E-10       0.017    6.30E-04              0.013          PNPT1           Intronic

  LCLs            rs62165226   2     55878339   C    0.484   MTCO3    2.79E-08   7.60E-03     2.71E-08       −0.018   6.80E-06              −0.018         PNPT1           Intronic

  Whole\          rs6973982    7     45143892   G    0.148   MTCO2    7.53E-31   8.60E-25     1.12E-30       −0.028   2.30E-08              −0.023         TBRG4           Intronic
  Blood                                                                                                                                                                    

  Whole\          rs6973982    7     45143892   G    0.148   MTCO3    1.23E-25   6.40E-20     1.05E-25       −0.028   1.40E-04              −0.019         TBRG4           Intronic
  Blood                                                                                                                                                                    

  Skin\           rs2304693    7     45148667   A    0.201   MTCO3    2.84E-12   2.10E-05     2.93E-12       −0.027   1.80E-03              −0.026         TBRG4           Missense
  (Not\                                                                                                                                                                    
  sun\                                                                                                                                                                     
  exposed)                                                                                                                                                                 

  Whole\          rs2304694    7     45148773   A    0.148   MTND1    2.34E-17   6.10E-12     3.19E-17       0.015    1.60E-08              0.024          TBRG4           Missense
  Blood                                                                                                                                                                    

  LCLs            rs2304694    7     45148773   A    0.197   MTND4    2.35E-18   3.90E-11     2.22E-18       −0.029   1.40E-04              −0.019         TBRG4           Missense

  Subcutaneous\   rs12579998   12    27861446   G    0.174   MTND1    2.48E-23   6.50E-17     1.09E-23       −0.032   3.20E-05              −0.032         \-              Intergenic
  Adipose                                                                                                                                                                  

  Subcutaneous\   rs12579998   12    27861446   G    0.174   MTND4    2.20E-12   1.70E-06     1.56E-12       −0.022   4.00E-04              −0.027         \-              Intergenic
  Adipose                                                                                                                                                                  

  Skin\           rs11049103   12    27862081   A    0.179   MTND1    7.72E-12   2.10E-05     6.68E-12       −0.022   8.10E-04              −0.026         \-              Intergenic
  (Not\                                                                                                                                                                    
  sun\                                                                                                                                                                     
  exposed)                                                                                                                                                                 

  Whole\          rs74863981   20    3109875    A    0.099   MTCO1\   4.24E-11   5.40E-06     5.25E-11       −0.024   6.60E-05              −0.022         UBOX5           Intronic\
  Blood\                                                                                                                                                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In order to uncover potential reasons for a lack of replication for some associations, we performed power analysis using the variance explained by each genetic variant on the associated mitochondrial encoded gene expression level in the discovery dataset, together with the replication sample size, and find that \~40.5 associations would be expected to replicate (at p=0.00082). Beyond this, we find significant differences between discovery and replication datasets for the proportion of mapped reads aligning to the mitochondrial genome in whole blood and subcutaneous adipose (Wilcoxon tests, p\<0.05 after correcting for multiple tests). It is unclear whether this would influence our ability to replicate associations in these cases, although we note that PEER factors (which we include as covariates in our association analyses) have been shown to correlate with known technical and biological features of RNA sequencing data ([@bib57]; [@bib19]; [@bib18]) and as such should control for some systematic variation across individuals. Even so, given the unexplained lack of replication in some cases, it is possible that false positives may contribute to our results.

To validate our results for one association (rs2304694-*MTND4* in LCLs) using an alternative RNA quantification method, we obtained LCLs with homozygous reference and non-reference genotypes at rs2304694, matched for sex and ethnicity between the two groups, and measured expression levels of *MTND4* using quantitative PCR. We find significant differences in the expression levels of *MTND4* between samples that are homozygous for the reference allele at rs2304694 versus samples that are homozygous for the non-reference allele at rs2304694 (p=0.0325, one-way ANOVA, [Figure 3B](#fig3){ref-type="fig"}), thus validating the original association with the same direction of effect.

Links to complex disease {#s2-5}
------------------------

Finally, since genetic variation modulating gene expression may underlie a large proportion of genetic associations with disease ([@bib43]), we intersected peak mitochondrial *trans*-genome eQTL SNPs, as well as those in strong linkage disequilibrium (LD, r^2^ \>0.8, calculated within our data), with significant associations documented in the NHGRI genome wide association study (GWAS) catalogue and find overlapping variants for two diseases/disease risk traits. First, the peak nuclear genetic variant associated with the expression of *MTCYB* in whole blood (rs782633) is in strong LD with rs782590, a variant that has been linked to systolic blood pressure (a known risk factor for heart disease and stroke) in a study of individuals with metabolic syndrome and controls ([@bib36]). We also note that the same peak nuclear genetic variant associated with the expression of *MTCYB* is also in LD with rs1975487 (r^2^ = 0.84 for Europeans in 1000 Genomes data), a variant that is associated with diastolic blood pressure in a larger GWAS for blood pressure ([@bib16]) (p=2×10^−9^). Rs1975487 was not present in our original analysis due to a missingness rate that was above our threshold for filtering (3%, 2% and 1.7% missing genotype rate in CARTaGENE, TwinsUK and GTEx data respectively). Mitochondrial processes have previously been associated with blood pressure ([@bib14]), and given the association here, this may at least partially be modulated though changes in mitochondrial encoded gene expression. The genetic variant associated with mitochondrial encoded gene expression falls within the intron of *PNPT1*, suggesting that this may be the gene of action influencing blood pressure, although further fine mapping and functional work would be required to establish a causal link.

Second, two peak genetic variants associated with the expression of *MTND5* and *MTND6* in whole blood (rs10172506 and rs7558127 respectively) are in strong LD with rs10200159, which has been associated with Vitiligo ([@bib31]), a disease that is driven by the functional loss of melanocytes in the skin which leads to a loss of pigmentation. High reactive oxygen species generation and a deficit of the antioxidant network are key processes in Vitiligo, and thus altered mitochondrial function is thought to play a role ([@bib12]). Although we detect significant associations in whole blood, there is suggestive evidence of the same relationships in sun-exposed skin data, with both associations occurring with p\<0.05 (p=0.016 and p=0.0027, GTEx data) and the same direction of effect. For both peak nuclear genetic variants the gene of action appears to be *PNPT1*, where we find evidence of significant mediation on the expression of *MTND5* and *MTND6* ([Table 1](#table1){ref-type="table"}).

Genome-wide association studies considering blood pressure were conducted in individuals of Finnish ([@bib36]) and European descent ([@bib16]), and the study of Vitiligo was also conducted using individuals of European descent ([@bib31]). Since our eQTL analysis included individuals from diverse ancestries (although largely of European descent), we attempted to match LD structure more closely to populations used in the above GWAS associations by re-running mitochondrial encoded eQTL analyses using only samples from individuals of European descent (see Materials and methods). Using the same approach as before, in whole blood data we find that rs782633 remains significantly associated with the expression of *MTCYB* in Europeans (p=6.33×10^−11^ in Europeans, p=8.58×10^−11^ in all samples), rs10172506 is significantly as associated with the expression of *MTND5* in Europeans (p=4.01×10^−25^ in Europeans, p=5.26×10^−32^ in all samples) and rs7558127 is significantly as associated with the expression of *MTND6* in Europeans (p=1.94×10^−31^ in Europeans, p=4.40×10^−40^ in all samples). Furthermore, we find that overlapping mitochondrial-encoded eQTL and GWAS variants are in strong LD in combined European populations surveyed by the 1000 Genomes project (r^2^ \>0.8 in all cases). These results imply that genetic variants associated with mitochondrial encoded gene expression are genuinely in LD with GWAS signals, however some caution should still be applied if populations within Europe are likely to generate further substructure in the data, which we have limited power to disentangle here.

Discussion {#s3}
==========

Despite key roles for mitochondria in a range of fundamental biological processes, as well as a wide array of human diseases, knowledge of how the mitochondrial transcriptome is processed across different individuals and tissues on a population scale is incomplete. Using RNA sequencing data for a large number of individuals and across a wide range of tissues, we find considerable variation in mitochondrial gene expression along the mitochondrial genome, across tissues and between individuals. Variation in mitochondrial encoded gene expression profiles is likely important for the cells ability to respond to changing energy demands in specific cell types and environments, and may also play a role in tissue specific disease processes across individuals.

Through integrated analysis of genetic and RNA data, we identify a large number of common nuclear genetic variants associated with mitochondrial encoded gene expression and replicate a substantial fraction of these (\~21% after correcting for multiple testing,\~41% at nominal 5% with the same direction of effect) in independent tissue-matched datasets. Through mediation analysis and functional genetic variants we identify the potential causal nuclear gene influencing mitochondrial encoded gene expression in 36 cases. A large number of these genes are already known to play a role in mitochondrial processes, and thus validate our findings in a biological context, but also implicate functional mechanisms by which common nuclear genetic variation can act between chromosomes (and indeed, genomes) to influence gene expression. Such *trans*-eQTLs have been notoriously difficult to replicate in humans, and thus the 13 replicated associations identified in this study provide candidates to test the mechanisms associated with genetic variation that acts over large genetic distances.

For some of the potential causal nuclear genes that we identify as being linked to variation in the expression mitochondrial-encoded genes, it is not difficult to speculate on potential mechanisms through which they might act. For example, *MTPAP* (within which we identify a missense mutation associated with the expression of *MTND3* in LCLs) synthesizes the poly(A) tail of mitochondrial transcripts. Since polyadenylation of mitochondrial transcripts is required in many cases to complete the termination codon and is thought to influence RNA stability ([@bib50]), a functional mutation in this enzyme may lead to variable accumulation of unprocessed mitochondrial transcripts and ultimately influence mitochondrial encoded gene expression levels. Similarly, *TBGR4* (within which we identify a missense mutation associated with the expression of multiple mitochondrial genes in multiple tissues) is known to process mitochondrial precursor transcripts and stabilize some mature mitochondrial messenger RNAs ([@bib7]), thus having obvious links to changes in mitochondrial gene expression. These findings lay the foundation for future work to functionally validate the causal role of these genetic variants.

Beyond this, we also identify nuclear genes through mediation analysis that have not previously been linked with mitochondrial gene expression. These results potentially point to novel roles for these proteins and thus may be important new targets in the context of mitochondrial disease in cases where it has thus far been difficult to identify causal mutations in patients. Examples that may be interesting for further study include *ZFP90*, a zinc finger protein that modulates nuclear gene expression. *ZFP90* transgenic mice show altered expression of genes involved in oxidative phosphorylation and fatty acid elongation in mitochondria compared to wild type littermates ([@bib63]), pointing to a potential role in mitochondrial processes. Similarly, *CCM2* is involved in the stress-activated p38 mitogen-activated protein kinase (MAPK) signalling cascade and is thought to localize to the mitochondria. CCM proteins are implicated in Cerebral Cavernous Malformation and accumulating evidence points to a role for these proteins in processes related to mitochondrial function, including cellular responses to oxidative stress and autophagy ([@bib51]).

Finally, the common genetic variants we identify here as associated with mitochondrial encoded gene expression profiles across individuals potentially have downstream functional consequences that influence disease processes and risk. We find some evidence for this, as nuclear genetic variation associated with variable mitochondrial encoded gene expression is linked to mutations that have been implicated in blood pressure and Vitiligo, yet further study of these genes is required to identify the causal mechanisms that influence how mitochondrial RNA is processed in the cell and how dysregulation of these mechanisms may cause disease. Combined, these data now serve as a frame of reference for mitochondrial disease researchers who wish to consider how patient samples may vary in mitochondrial gene expression versus a healthy cohort in the relevant tissue type, and for the community as whole interested in the genes and genetics of fundamental processes taking place in mitochondria and the genetic architecture of gene expression.

Materials and methods {#s4}
=====================

Data {#s4-1}
----

Raw human RNA sequencing and genotyping data were obtained through application to five independent sequencing projects:

*CARTaGENE*: CARTaGENE is a healthy cohort of individuals aged between 40 and 69 from Quebec, Canada. Whole blood, 100 bp paired-end RNA sequencing and genotyping data (Illumina Omni 2.5M arrays) for 911 individuals were obtained from the CARTaGENE project ([@bib4]; [@bib25]) through application to the data access committee (instructions are available at [www.cartagene.qc.ca](http://www.cartagene.qc.ca)). Samples with multiple sequencing runs were merged prior to alignment.

*TwinsUK*: 50 bp paired-end RNA sequencing data from 391 whole blood samples, 685 subcutaneous adipose samples, 672 non-sun exposed skin samples and 765 LCL samples ([@bib8]), as well as accompanying genotyping information (obtained from either Illumina HumanHap300 and HumanHap610Q arrays), were derived from a mix of unrelated samples and monozygotic and dizygotic twin pairs through application to the TwinsUK data access committee and then downloaded from the European Genome-Phenome archive (<https://ega-archive.org>) through study ID EGAS00001000805.

*GTEx (Genotype-Tissue Expression) Project:* 75 bp paired-end RNA sequencing data from 44 tissue/cell types from up to 572 individuals ([@bib19]), along with accompanying genotyping data (obtained from either Illumina Omni5M and Omni2.5M arrays) were obtained by application to dbGaP through accession number phs000424.v6.p1. Tissues were selected if the organ they were obtained from had at least 100 samples. In cases where samples had multiple sequencing experiments for a given individual and tissue, we selected the dataset containing the highest number of raw sequencing reads.

*NIMH (National Institute of Mental Health) Genomics Resource*: 50 bp single end RNA sequencing data and matched genotyping data (Illumina HumanOmni1-Quad BeadChip) from 937 whole blood samples ([@bib6]; [@bib42]) from the Depression Genes and Networks study were obtained via transfer from external hard drives after application to the data access committee (through [www.nimhgenetics.org](http://www.nimhgenetics.org)).

*Geuvadis Project*: 75 bp paired end RNA sequencing data from 462 LCL samples ([@bib39]) were downloaded from the European Nucleotide Archive under submission number ERA169774. Accompanying genetic variants from whole genome sequencing data (which were generated as part of the 1000 Genomes Project ([@bib1])) were downloaded from the 1000 genomes FTP site. We used phase three data that was phased and imputed (v5a.20130502).

Processing of RNA sequencing data {#s4-2}
---------------------------------

All RNA sequencing data derived from different projects were processed in the same way to ensure comparability across analyses. Raw RNA sequencing reads (fastq format) from 13,261 individual samples were trimmed for adaptor sequences, terminal bases with nucleotide quality below 20 and poly(A) tails \> 4 bp in length, before being aligned to a reference genome (1000G GRCh37 reference, which contains the mitochondrial rCRS NC_012920.1) with STAR 2.51a ([@bib15]), using two-pass mapping, version 19 of the Gencode gene annotation and allowing for 1/18\**read_length* mismatches, rounded down to the nearest integer. Following this, in order to minimize the likelihood of incorrectly placed reads (particularly those associated with NUMT sequences), we used a stringent filtering pipeline, focusing only on reads that were properly paired and uniquely mapped. After mapping we removed low quality samples that had either \<10 thousand reads mapping to the mitochondrial genome,\<5 million total mapped reads,\>30% of reads mapping to intergenic regions,\>1% total mismatches or \>30% reads mapping to ribosomal RNA using in house scripts and RNAseQC ([@bib13]). To calculate transcript abundances, we used HTseq ([@bib3]) with the 'intersect non-empty' model and version 19 of the Gencode gene annotation, before converting raw counts to transcripts per million (TPM). We plotted the log~10~ transformed distributions of all genes with mean TPM \>2 per sample and removed visual outlier samples. We also calculated principle components using the same data and removed outlier samples. Finally, samples were only included in analyses if they had accompanying high quality genotyping information (see below) and there were at least 70 samples available for analysis within each tissue/dataset; in total after matching samples to genotyping data and quality control filtering we were left with 11,371 RNA sequencing datasets for analysis. We focused on mitochondrial encoded protein coding and ribosomal RNA genes only, since transfer RNAs showed lower sequencing coverage overall and were not expressed highly in all tissues and datasets. For analysis of mitochondrial encoded gene expression variation across genes and datasets, for TwinsUK data we used only unrelated samples (which involved picking one of each twin pair at random and combining these with unrelated samples). For NIMH samples, which were derived from 454 depression cases and 454 controls, we tested whether disease status may affect our results by comparing TPM values for mitochondrial-encoded genes between the two groups; in all cases we find no significant differences (Wilcoxon test, p\>0.05 in all cases after correction for multiple testing).

Processing of genotyping data {#s4-3}
-----------------------------

Genotyping data from different arrays and sequencing studies were processed separately. For TwinsUK data, only one twin from each twin pair was genotyped and thus processed, with data duplicated to represent the missing twin pair after quality control and filtering. Genotyping quality control and calculation of genetic principle components for Twins data was thus performed only on unrelated samples. Within each dataset, samples with high relatedness (\>0.125), high SNP heterozygosity (visual outliers), non-matching sex, ambiguous X-chromosome homozygosity estimates or high SNP missingness (\>5%) were removed. Autosomal SNPs were flipped to the positive strand and those with minor allele frequency (MAF) \>1%, in Hardy Weinberg equilibrium (p\>0.001) and not missing in more than 1% of individuals were then phased with shapeit2 ([@bib11]) using no reference panel and default settings. Problematic sites were removed and remaining SNPs were used for imputation in 2 MB intervals using impute2 ([@bib27]) with default settings, incorporating the 1000 Genomes phase three reference panel. Imputed data were then hard-called to produce genotypes at each site with a threshold of 0.9 and SNPs with information score lower than 0.8 were removed. Data from different arrays within each study were then merged and filtered to keep bi-allelic variants with minor allele frequency (MAF) \>5%, in Hardy Weinberg equilibrium (p\>0.001) and not missing in more than 1% of individuals for downstream analysis. After processing, we calculated genetic principal components and removed outlier samples by visual inspection. For Geuvadis data we used whole genome sequencing variant calls from the 1000 Genomes project ([@bib1]). As such, these samples did not undergo phasing and imputation within our pipeline, but were filtered in the same way as genotyping data after this stage of the analysis.

Association analyses {#s4-4}
--------------------

Expression QTL mapping was performed within each tissue and sequencing dataset. In each case, TPM values for thirteen mitochondrial encoded protein coding genes and two mitochondrial encoded ribosomal RNA genes were extracted before being log~10~ transformed ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). Mitochondrial encoded gene expression distributions were median normalized, before outlier values were removed per gene (defined as three interquartile ranges above or below the upper and lower quartile respectively). To control for unidentified confounding factors in RNA sequencing data, we calculated PEER factors ([@bib57]) per dataset using all genes (nuclear and mitochondrial) that had a mean TPM \>2. For genotyping data, we restricted the data to only those samples that had corresponding mitochondrial encoded gene expression values for the given dataset and calculated genetic principle components on this reduced set in each case. We then performed association analyses on each tissue and dataset using a linear model within PLINK ([@bib48]) for unrelated samples. For twin data, we calculated the relatedness matrix of samples before conducting association analyses with GEMMA ([@bib64]). In each case we included sex, five genetic principle components, 5 or 10 PEER factors (five for samples sizes \< 100, ten for sample sizes \>= 100) and sequencing/genotyping batch (where applicable) as covariates. For TwinsUK data, the genotyping array was included as the batch covariate and sex was omitted as all samples were derived from females. For CARTaGENE data, which was original sequenced at higher and lower coverage as part of discovery and replication phase data respectively ([@bib25]), the sequencing phase was included as the batch covariate. For GTEx data, where two different genotyping arrays were used, the genotyping array covariate correlated highly with one of the first genetic principle components for all tissues (\|r\| \> 0.8 in all cases) and was therefore not included in the linear model. After analysis, QQ plots were visually assessed and show no skew. QQ plots for discovery associations that replicate at the nominal 5% level are shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. False discovery correction (Benjamini-Hochberg) was applied to raw p-values within each dataset by merging all genes (15) and genetic variants in each case, following the approach applied by the GTEx consortium ([@bib19]).

To calculate P-values via permutation analysis, for each association that we originally identified as being significant at FDR 5% (64 variant-gene pairs), we performed 100,000 point-wise permutations for the relevant tissue type, mitochondria-encoded gene and nuclear genetic variant by randomly shuffling phenotypes. In each case, we then collected the test statistic across all 100,000 permutations to generate a null distribution, and compared our observed test statistic against this to calculate an empirical P-value. For tissue types with multiple datasets (Whole Blood and LCLs) we performed permutations per dataset, combined these within a meta-analysis, and then derived the null distribution from the meta-analysis results. In each case, we also then followed the approach outlined in [@bib46] to calculate a more precise P-value by estimating the underlying beta distribution of the null distribution via maximum likelihood (using the 'ebeta' function within the R package 'EnvStats').

Additionally, we also calculated the family-wise error rate on the gene level for each association originally detected at FDR 5%. To do this, we performed 200 random permutations across all nuclear genetic variants for the relevant mitochondria-encoded gene and tissue type, and then calculated the null distribution by selecting the largest test statistic per permutation across all nuclear genetic variants. To calculate the overall family wise error rate, we repeated this again, this time selecting the largest test statistic across all nuclear genetic variants and all 15 mitochondria-encoded genes per permutation to generate the null distribution in the relevant tissue type. For the calculation of both family-wise error rates, we repeated the approach outlined in [@bib46] to obtain a more precise P-value by extrapolating from the beta-distribution generated from the null. P values generated across all methods are shown in [supplementary file 1](#supp1){ref-type="supplementary-material"}.

NUMT sequences were obtained from the UCSC genome browser track named 'numtS', and were generated by [@bib55], who used blastN to map nuclear chromosomes to the mitochondrial genome, setting the e-value threshold to 0.001. Sequences in this database range from 31 to 14904 bp in length, with a similarity percentage ranging between 63% and 100%, thus the approach has the potential to tolerate a large number of mismatches between nuclear and mitochondrial sequences. To test whether any 50 bp segments of mitochondrial genes also aligned to nuclear genes, we followed the approach defined in [@bib52]. Specifically, we took all 50 bp k-mers from each mitochondrial encoded gene and then aligned these sequences to the nuclear genome using bowtie v1.22 ([@bib38]), allowing for up to two mismatches and reporting all alignments. For each nuclear genetic variant associated with a mitochondrial encoded gene, we then tested whether any of the 50 bp k-mers from the mitochondrial encoded gene aligned within a nuclear gene whose transcription start site fell within 1 MB of the corresponding nuclear genetic variant.

For tissue types with multiple independent datasets, we defined discovery and replication datasets. Discovery datasets were chosen as the dataset with the largest starting sample size for each given tissue, with the replication dataset as the second largest. For whole blood, where four independent datasets were available, we performed meta analysis within PLINK using a fixed affects model, combining data from the CARTaGENE project, GTEx and TwinsUK for the discovery phase, and then used NIMH data for replication. For LCLs, where three independent datasets were available, we performed meta analysis combining data from the Twins and GTEx for the discovery phase, and then used Geuvadis data for replication. For Subcutaneous adipose and non-sun exposed skin, we used TwinsUK data for discovery and GTEx data for replication. For all other tissues, only a single dataset was available, and so no replication analysis was performed. In all association analyses we defined the peak SNP as the genetic variant with the lowest p-value within a block of 1 MB, and tested for replication using the exact same SNP where available (using the nearest SNP in LD (r^2^ \>0.8) if the exact match was not present, followed by the nearest SNP with r^2^ \>0.5 otherwise). We used the same approach when comparing association signals across tissues. To perform power calculations, we obtained the correlation coefficient (r^2^) between the genetic variant and the expression of the associated mitochondrial encoded gene in the relevant discovery dataset (or largest dataset where the genetic variant is present, if multiple datasets are available for the tissue). We then used a power calculator ([@bib47]), specifying our estimate for the variance explained by the genetic variant (r^2^), the minor allele frequency, replication sample size and the significance threshold (0.05/61) in each case. Following this, we summed power values across all 61 associations.

We also repeated all association analyses after using mitochondrial library size (all reads mapping to the mitochondrial) to calculate TPM for mitochondrial genes, rather than total library size. We tested this approach as a way to remove the effects of variable mitochondrial copy number and poly-cistronic transcription rate, however in all cases we obtained very similar results to those obtained using the method outlined above. Additionally, we also repeated all analyses shown in [Figure 1](#fig1){ref-type="fig"} using mitochondrial reads to normalize gene expression values; again we find very similar results.

It has recently been shown that the post-mortem interval (PMI) appears to influence gene expression patterns in GTEx data ([@bib17]). As such, to test for an effect in our data, we repeated association analyses for significant associations discovered in GTEx data and including PMI as a covariate (where PMI data were available). In both cases, we find that the P-values do not change dramatically (Atrial appendage (heart), rs11811165-*MTND4L*, original raw P value: 5.09 × 10^−10^, P value including PMI as a covariate: 3.50 × 10^−9^; Tibial nerve, rs932345-*MTND4L*, original raw P value: 6.47 × 10^−10^, P value including PMI as a covariate: 7.57 × 10^−10^).

Functional annotation and links to complex disease {#s4-5}
--------------------------------------------------

In order to identify the potential causal nuclear gene associated with mitochondrial encoded gene expression, we identified genes associated with the peak eQTL variant in the following ways. First, if the peak variant was a missense mutation, we assumed that its mode of action was via functional changes in the gene it was located in. Second, for non-coding mutations, we tested whether non-coding peak variants fell in enhancer regions using chromatin state predictions obtained from 128 cell types within the Roadmap Epigenetic project ([@bib37]), using matched tissue data as outlined in the GTEx project ([@bib19]), and compared this against a set of random genetic variants matched for minor allele frequency, distance from transcription start site and genome annotation (using 1000 random sets to generate a P-value). Third, for non-coding peak variants, we tested for mediation via the expression of nuclear genes located near to the peak SNP. To do this, for each tissue we used the largest dataset available and restricted our analysis to unrelated samples (for TwinsUK data, this involved picking one of each twin pair at random and combining these with unrelated samples). Within each dataset we then again tested for a significant correlation between the peak SNP and the expression of the mitochondrial gene in question (p\<0.05, linear model, t-test of regression coefficient), as well as a significant correlation between the peak SNP and the expression of any nuclear gene within 1 MB of the variant (p\<0.05, linear model, t-test of regression coefficient). For genes/variants passing these criteria, we then tested whether the expression of the nuclear gene significantly mediated the relationship between the peak nuclear variant and the mitochondrial encoded gene expression using the module 'mediation' (testing significant mediation of the initial association via bootstrapping, requiring an average causal mediation effect with p\<0.05 after FDR correction) within R. To prioritize potential causal genes within this framework, we first selected nuclear genes with a known role in mitochondrial processes (any gene listed in the Mitocarta database ([@bib9]), shown to influence mitochondrial RNA processing ([@bib61]) or listed as being involved in mitochondrial disorders in the Genomics England PanelApp - <https://panelapp.genomicsengland.co.uk>), before moving on to any other nuclear gene. Finally, we tested whether non-coding peak variants were associated with the expression of more distal genes (those whose transcription start site was \>1 MB away, or on another chromosome) within a linear model (and meta-analysis where relevant) including the same datasets, methods and covariates as the original discovery analysis.

In order to identify whether genetic variants associated with mitochondrial encoded gene expression may play a role in complex disease, we first identified any SNP in linkage disequilibrium (r^2^ \>0.8, calculated using datasets and samples used in this study) with peak eQTL SNPs in any of the datasets used for the tissue type in which the association was identified. We then tested whether any of these variants overlapped with significant associations documented in the NHGRI GWAS catalogue (for association where p\<5e-8). To test whether associations between nuclear genetic variants and mitochondrial encoded gene expression that overlap GWAS signals are significant in individuals of European descent, we plotted the first two genetic principal components against those derived from 1000 genomes samples with known ancestry for any dataset that had associated RNA sequencing data from whole blood. We then selected samples that clustered with Europeans in 1000 genomes data by visual inspection and re-ran association analyses as before for whole blood data from CARTaGENE, TwinsUK and GTEx, before performing meta-analysis to calculate P-values.

Validation {#s4-6}
----------

In order to validate the association between rs2304694 and expression levels of *MTND4* in LCLs, we obtained ten LCL samples carrying the homozygous reference genotype and ten LCL samples carrying the homozygous non-reference genotype for rs2304694 from the Coriell Institute for Medical Research, matched between the two genotype groups for sex and ethnicity ([Supplementary file 5](#supp5){ref-type="supplementary-material"}). The following cell lines were obtained from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research: GM11919, GM11932, GM12003, GM12414, GM12717, GM12842. The following cell lines were obtained from the NHGRI Sample Repository for Human Genetic Research at the Coriell Institute for Medical Research: GM20582, GM20822, HG00118, HG00254, HG00284, HG00290, HG01524, HG01625, HG01631, HG01777, HG01800, HG01804, HG01812, HG01815. Cultures were tested as standard by Coriell Cell Repositories before shipping and found free of mycoplasma, and microsatellite profiling was used to confirm identity (see 'Quality Control' at [www.coriell.org](http://www.coriell.org)). Cells were handled as per supplier's instructions. Total RNA was extracted using the RNeasy kit (Qiagen) according to the manufacturer\'s instructions. 1 ug total RNA was pre-treated with 2 units of Turbo DNase (Fisher Scientific) and subsequently reverse-transcribed using the ProtoScript First Strand cDNA synthesis kit (New England BioLabs) with random primers. The first strand reaction was diluted five fold with deionised water and 1% (vol/vol) was used as template for each real-time PCR (RT-PCR) reaction. RT-PCR was carried out using QuantiNova SYBR Green (Qiagen) and a StepOnePlus RT-PCR System (Applied Biosystems). Primers used were as follows: *GAPDH* (F: TCTGCTCCTCCTGTTCGACA, R: AAAAGCAGCCCTGGTGACC), *MTND4* (F: CACTAAACATTCTACTACTCACTCTC, R: GGAGTCATAAGTGGAGTCCGTA). Expression levels of *MTND4* were determined after normalization to *GAPDH* (theoretical quantities), and two technical qPCR replicates were performed per sample before being averaged. Outlier values were removed (defined as three interquartile ranges above or below the upper and lower quartile respectively) within each genotypic category, leaving 19 samples for analysis. This association was chosen for replication analysis since it is associated with mitochondrial encoded gene expression across multiple tissue types and is significantly associated with *MTND4* in a dataset and tissue type for which we had access to the relevant biological material (Geuvadis dataset, LCLs).
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###### Population, sex and allele information for cell lines used in qPCR validation experiments.
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###### Forest plots for each peak variant detected in association analyses.

Each plot contains Beta estimates and confidence intervals for each of the datasets and tissues considered in the study.
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Data availability {#s7}
=================

Anonymized processed mitochondrial encoded gene expression matrices are available in Supplementary file 2 and from the Gene Expression Omnibus under accession GSE125013. Data from CARTaGENE (Awadalla et al., 2013) and NIMH sequencing data from the Depression Genes and Networks study (Battle et al., 2014) used in this work are available through request. Requests for access first need to be approved by a data access committee (further information can be found here <https://www.cartagene.qc.ca/en/researchers/access-request> and here <https://www.nimhgenetics.org/request-access/how-to-request-access>).

The following dataset was generated:

AliATBoehmeLCarbajosaG2019Nuclear Genetic Regulation of the Human Mitochondrial TranscriptomeNCBI Gene Expression OmnibusGSE125013

The following previously published datasets were used:

BuilABrownAALappalainenTVinuelaADaviesMN2015Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twinsEuropean Genome-Phenome ArchiveEGAS00001000805

GTExConsortium2017Common Fund (CF) Genotype-Tissue Expression Project (GTEx)NCBI dbGaPphs000424.v6.p1

LappalainenT2013Geuvadis ProjectEuropean Nucleotide ArchiveERA169774
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Nuclear Genetic Regulation of the Human Mitochondrial Transcriptome\" for consideration by eLife. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a guest Reviewing Editor and Mark McCarthy as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Dan Arking (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. As you can see, we have listed a set of \"essential revisions\" that represent the consensus assessment of the editors and reviewers.

Summary:

The manuscript describes a study of the regulation of the mitochondrial transcriptome, in particular identifying nuclear genetic variants that are associated with expression of mitochondrial transcripts. They identify such associations for fourteen out of fifteen mitochondrial genes and a total of 64 trans-genome associations. Replication between studies is observed, and they discuss the role of genetic variation affecting mitochondrial gene expression in complex disease.

The reviewers appreciated the importance of the findings for understanding mitochondrial gene expression and found the manuscript generally clear. However, to support the findings, some additional analyses are desired along with adding to the biological interpretation of the results and the discussion of some caveats.

Essential revisions:

1\) In order to achieve a higher level of biological understanding and impact of the results, it is necessary to more fully characterize the discoveries, particularly those that are not previously implicated in known mitochondrial regulatory processes. This could include an analysis of the variability in expression of those factors; a more systematic analysis of whether those factors are shuttled back to the nucleus or localized with the mitochondria; and analysis of the 45 QTLs that are not missense mutations. For instance, are they in known enhancer regions that may have impacts on multiple mt-regulatory factors? Are the same QTLs (either SNPs or linked SNPs) also associated with nuclear encoded mitochondrial genes that have interconnected signaling pathways with mt encoded genes. Are the gene expression levels of these two sets of mt genes associated with each other across individuals and could there be any regulatory feedback mechanisms across these sets of genes? Not every one of these questions will necessarily yield an interesting result, but some further expansion on biological interpretation is necessary.

2\) Replication rate overall is low, which merits exploration. Is this due to power, technical variability, biological variability, or a higher false discovery rate than originally estimated? It is necessary to show analysis attempting to disentangle this through power calculation, simulation, and any relevant demonstration of biological or technical confounders. Could it be driven by differences in mt copy number, or cell state (leading to differences in mt-liked metabolic activity)?

Given low replication rates and other concerns, it is noted that FDR may be susceptible to artifacts, and in general it is necessary to demonstrate that the FDR is well calibrated. The suggested method is to use permutation analysis (permuting a trait, leaving linkage disequilibrium intact) to establish an empirical null. In addition, please include raw p-values along with FDR for detected associations.

3\) In order to rule out false positive trans associations due to alignment error, it is necessary to evaluate whether there is sequence similarity between the candidate mt eQTL target genes and the nuclear regions of the genome, particularly for regions near the candidate eQTL variants. If there is sequence similarity, these could represent cis-eQTLs or nuclear eQTLs for genes that simply have some reads mis-mapping to mt. This is a similar problem to probe cross-hybridization observed for microarrays, and has been observed for RNA-seq false positive trans-eQTLs in GTEx and other studies.

4\) It is necessary to address questions regarding ancestry and linkage disequilibrium, particularly considering diverse ancestries represented in the RNA-seq data and potential differences with those in the GWAS data used. The manuscript evaluates SNPs in NHGRI GWAS catalogue in strong LD with the SNPs that control mtDNA gene expression. What LD reference is used? Is it the European LD reference calculated from 1000 genomes, or is it the in-sample LD from the datasets with RNAseq data? What were the populations (ancestries) in which the GWAS was performed? In other words, is the LD between SNPs calibrated for the GWAS or for the eQTL analyses? While it may not be possible to match LD perfectly between GWAS and eQTL analyses, these potential issues should be mentioned and some attempt made to determine if they are problematic. If the individual data is available, it is necessary to discuss single/per population analysis to show that their results are real and not artifacts of population structure and also likely consistent across populations. This would involve simply sectioning out the samples from each single population, and rerunning their analysis. The associations are not expected to be significant in the single population analysis since they\'ll have much smaller sample sizes, but the effect sizes and directions should be correlated. If this is not possible, then caveats of population structure need to be mentioned and the claims toned down accordingly.
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Author response

> Essential revisions:
>
> 1\) In order to achieve a higher level of biological understanding and impact of the results, it is necessary to more fully characterize the discoveries, particularly those that are not previously implicated in known mitochondrial regulatory processes. This could include an analysis of the variability in expression of those factors; a more systematic analysis of whether those factors are shuttled back to the nucleus or localized with the mitochondria; and analysis of the 45 QTLs that are not missense mutations. For instance, are they in known enhancer regions that may have impacts on multiple mt-regulatory factors? Are the same QTLs (either SNPs or linked SNPs) also associated with nuclear encoded mitochondrial genes that have interconnected signaling pathways with mt encoded genes. Are the gene expression levels of these two sets of mt genes associated with each other across individuals and could there be any regulatory feedback mechanisms across these sets of genes? Not every one of these questions will necessarily yield an interesting result, but some further expansion on biological interpretation is necessary.

We now perform additional analyses to better understand the impact of our results. First, as suggested, we tested whether non-coding variants are enriched in enhancer regions using chromatin state predictions obtained from 128 cell types within the Roadmap Epigenetic project. We find that none of the non-coding nuclear genetic variants associated with mitochondrial encoded gene expression fall in enhancer regions in tissue matched cell types (data available for 44 of the 49 variants), which is not different to that expected by chance (P=0.676, using randomly selected variants matched for minor allele frequency, distance to nearest transcription start site and annotation). Under the assumption that associations between nuclear genetic variants and mitochondrial encoded gene expression occur ubiquitously across the body (and we don't have the power to detect these associations in all tissues), we tested for the presence of peak variants in enhancer regions in any cell type. In total, 24 variants fall in enhancer regions, which is again not significantly different from random (P=0.691, using randomly selected variants as before).

Second, since we already analyse the impact of non-coding peak variants on nuclear gene expression in *cis*, we also test whether peak variants act over larger genetic distances and are associated with the expression of nuclear genes in *trans*. Performing association analyses between all non-coding peak variants and the expression of all nuclear genes whose transcription start sites are more than 1MB away (or on different chromosomes), we find no significant associations after Bonferroni correction.

Our existing results show that some peak variants fall at functional positions within known nuclear encoded mitochondrial genes. We have also shown that many non-coding peak variants are not only associated with the expression of nearby nuclear genes, but also that the expression of these nuclear genes correlate with the expression of the corresponding mitochondrial encoded gene, and moreover, this correlation explains a significant proportion of the originally detected relationship between the peak nuclear variant and the expression of the mitochondrial encoded gene (mediation analysis). Combining the results from the two new analyses suggested by the reviewers/editors (where we see no evidence of peak variants falling in enhancer regions or influencing the expression of more distal genes), it seems that the mechanisms of action driving the *trans*-genome associations that are most consistent with our results are either directly functional on gene (through a missense mutation), or acting via the expression of a gene in *cis* (identified via mediation analysis) where the peak variant is either not causal itself (but is in LD with the causal mutation) or influences the gene via a mechanism not associated with the actions of known enhancers.

Third, given the above, we further annotate genes identified through functional mutations or mediation analysis via Mitominer (Smith and Robinson, 2016), an integrated resource for mitochondrial localisation and functional evidence. Of the genes identified through functional mutations (*TBRG4, LONP1, MTPAP*), there is evidence that all three proteins are targeted to the mitochondria, and mass spectrometry experiments have identified evidence of these proteins in mitochondria. Furthermore, *TBRG4* and *MTPAP* contain RNA binding domains (Wolf and Mootha, 2014), and so may influence mitochondrial RNA directly. For genes identified through mediation analysis, 7 of them have previously been linked to mitochondrial processes and are predicted to contain mitochondria targeting sequences. Within these, five genes are thought to contain RNA binding domains (*TBRG4*, and *MTPAP* as before, as well as *MRPP3, PNPT1* and *LRPPRC*). For genes not yet linked to mitochondrial processes, *SLC7A6OS* and *TGM3* show partial evidence of being targeted to mitochondria in some databases (*SLC7A6OS* is predicted to contain a mitochondria-targeting sequencing by IPSort, and both genes have a TargetP score \>0.6 (Smith and Robinson, 2016)). Furthermore, we have previously described potential experimental links of some of these genes to mitochondrial processes. For example, *ZFP90* transgenic mice show altered expression of genes involved in oxidative phosphorylation and fatty acid elongation in mitochondria compared to wild type littermates (Yang et al., 2009), pointing to a potential role in mitochondrial processes.

In line with this new work, we have now added a description of the two new analyses to the Materials and methods subsection "Functional Annotation and links to Complex Disease", as well as to the Results subsection \" Functional characterization". We also supplement existing annotation of the nuclear genes that we link to mitochondrial encoded gene expression using information obtained from Mitominer and associated databases.

> 2\) Replication rate overall is low, which merits exploration. Is this due to power, technical variability, biological variability, or a higher false discovery rate than originally estimated? It is necessary to show analysis attempting to disentangle this through power calculation, simulation, and any relevant demonstration of biological or technical confounders. Could it be driven by differences in mt copy number, or cell state (leading to differences in mt-liked metabolic activity)?
>
> Given low replication rates and other concerns, it is noted that FDR may be susceptible to artifacts, and in general it is necessary to demonstrate that the FDR is well calibrated. The suggested method is to use permutation analysis (permuting a trait, leaving linkage disequilibrium intact) to establish an empirical null. In addition, please include raw p-values along with FDR for detected associations.

We have now performed power calculations to test whether a lack of replication in some cases may be a consequence of small sample sizes for replication datasets. To do this for each significant association, we obtained the correlation coefficient (r^2^) between the genetic variant and the expression of the associated mitochondrial encoded gene in the relevant discovery dataset (or largest dataset where the genetic variant is present, if multiple datasets are available for the tissue). We then used a power calculator (Purcell et al., 2003), specifying our estimate for the variance explained by the genetic variant (r^2^), the minor allele frequency, replication sample size and the significance threshold (0.05/61) in each case. Following this, we summed power values across all 61 associations and found that we have power to replicate \~40.5 of the 61 associations identified in the discovery phase. Beyond this, in terms of other biological/technical features, although we cannot measure mitochondrial copy number directly, we find significant differences between discovery and replication datasets for the proportion of mapped reads aligning to the mitochondrial genome in whole blood and subcutaneous adipose (Wilcoxon tests, P\<0.05 after correcting for multiple tests). It is unclear whether this would influence our ability to replicate associations in these cases. We note that PEER factors (which we include as covariates in our association analyses) have been shown to correlate with known technical and biological features of RNA sequencing data (Stegle et al., 2010; Consortium et al., 2017; Glastonbury et al., 2018) and as such should control for some systematic variation across individuals. This additional analysis and discussion of caveats affecting the replication rate have now been included in the results section, as follows:

"In order to uncover potential reasons for a lack of replication for some associations, we performed power analysis using the variance explained by each genetic variant on the associated mitochondrial encoded gene expression level in the discovery dataset, together with the replication sample size, and find that \~40.5 associations would be expected to replicate (at P=0.00082). \[...\] Even so, given the unexplained lack of replication in some cases, it is possible that false positives may contribute to our results."

The methods for this analysis are described as follows:

"To perform power calculations, we obtained the correlation coefficient (r^2^) between the genetic variant and the expression of the associated mitochondrial encoded gene in the relevant discovery dataset (or largest dataset where the genetic variant is present, if multiple datasets are available for the tissue). We then used a power calculator (Purcell et al., 2003), specifying our estimate for the variance explained by the genetic variant (r^2^), the minor allele frequency, replication sample size and the significance threshold (0.05/61) in each case. Following this, we summed power values across all 61 associations."

We have now also performed permutation analysis as suggested by permuting each trait and leaving linkage disequilibrium intact, in order to test whether the original association tests and FDR correction are well calibrated. We performed the following three types of permutation and correction:

1\) Point-wise permutations: For each association that we originally identify as being significant at FDR 5% (64 variant-gene pairs), we performed 100,000 point-wise permutations for the relevant tissue type, mitochondria-encoded gene and nuclear genetic variant by randomly shuffling phenotypes. In each case, we then collected the test statistic across all 100,000 permutations to generate a null distribution, and then compared our observed test statistic against this to calculate an empirical P-value. For tissue types with multiple datasets (Whole Blood and LCLs) we performed permutations per dataset, combined these within a meta-analysis, and then derived the null distribution from the meta-analysis results. In each case, we also then followed the approach outlined in Ongen et al., 2016 to calculate a more precise P-value by estimating the underlying beta distribution of the null via maximum likelihood (using the "ebeta" function within the R package "EnvStats"). P-values obtained via this method closely follow raw P-values, and are now reported in Supplementary file 1 and Table 2.

2\) Family wise error rate at the gene level: Following the approach above, we also performed 200 random permutations within each tissue per mitochondria- encoded gene for all nuclear genetic variants in each dataset. We then calculated the null distribution by selecting the largest test statistic across all nuclear genetic variants within each gene per permutation, and compared the observed test statistic for the relevant originally detected significant association to this null distribution in order to calculate the family wise error rate on the gene level. We also generated a more precise P-value in each case by estimating the underlying beta distribution of the null as above.

3\) Family wise error rate across genes: Finally, we also repeated the above approach, but generated the null distribution in each case using the largest test statistic across all nuclear genetic variants and all 15 mitochondria-encoded genes per permutation to calculate the overall family-wise error rate. Again, we also generate a more precise P-value in each case by estimating the underlying beta distribution of the null.

We continue to present downstream analysis of all associations detected at FDR 5%, and clearly document which variants are significant through permutation analyses in Table 2 and Supplementary file 1, so that the reader may draw their own conclusions about the biological implications of variants detected by applying different significance thresholds. Results from this analysis are now noted in the second paragraph of the Results subsection "Nuclear control of mitochondrial gene expression", and described in the Materials and methods section as follows: "To calculate P-values via permutation analysis, for each association that we originally identified as being significant at FDR 5% (64 variant-gene pairs), we performed 100,000 point-wise permutations for the relevant tissue type, mitochondria-encoded gene and nuclear genetic variant by randomly shuffling phenotypes. \[...\] P values generated across all methods are shown in supplementary file 1."

We also note that the direction of effect was previously incorrectly noted for one association in the replication data (rs62165226, *MTCO3* in LCLs). We have now corrected this in Table 2 and as a result, we find that 13 of the 61 associations significant at 5% FDR now replicate in independent tissue matched datasets (\~21%). We have corrected this value in the Abstract, in the results section and in the Discussion.

> 3\) In order to rule out false positive trans associations due to alignment error, it is necessary to evaluate whether there is sequence similarity between the candidate mt eQTL target genes and the nuclear regions of the genome, particularly for regions near the candidate eQTL variants. If there is sequence similarity, these could represent cis-eQTLs or nuclear eQTLs for genes that simply have some reads mis-mapping to mt. This is a similar problem to probe cross-hybridization observed for microarrays, and has been observed for RNA-seq false positive trans-eQTLs in GTEx and other studies.

To rule out false positive trans-genome associations driven by alignment error, we tested for the presence of nuclear encoded mitochondrial sequences (NUMTs) in the regions around each peak nuclear genetic variant that is associated with mitochondrial-encoded gene expression. NUMTs are mitochondrial DNA sequences that have transposed into the nuclear genome over evolutionary time scales, and as such often retain moderate to high sequence similarity with the mitochondrial genome. Specifically, we first obtained known NUMT sequences from the UCSC genome browser, which were generated by Simone et al., 2011, who used blastN to map nuclear chromosomes to the mitochondrial genome, setting the e-value threshold to 0.001. Sequences in this database range from 31 to 14904bp in length, with a similarity percentage ranging between 63% and 100%, thus the approach has the potential to tolerate a large number of mismatches between nuclear and mitochondrial sequences. Then, for each peak nuclear genetic variant that is associated with the expression of a mitochondrial-encoded gene we tested for the presence of at least 50bp of that gene in each NUMT (the shortest read length in our analysis) within 1MB of the corresponding nuclear variant. In total we find two such occurrences (out of 64 peak variants) and we observe \~4 and \~15 mismatches per 100bp in these sequences compared to the corresponding mitochondrial encoded sequence. Additionally, for each peak nuclear genetic variant that is associated with the expression of a mitochondrial-encoded gene, we also tested whether any 50bp segment of the mitochondrial-encoded gene also mapped to a nuclear gene (following the approach defined in (Saha and Battle, 2018)) that has its transcription start site within 1MB of the corresponding peak nuclear variant; we find no such occurrences. As such, it seems unlikely that alignment error is driving our associations.

We have now included these analyses in the results section as follows:

"To ensure that trans-genome eQTLs are not driven by alignment errors that are a consequence of sequence similarity between the nuclear and the mitochondrial genomes, we tested for the presence of nuclear mitochondrial DNA segments (NUMTs) in the regions surrounding each peak nuclear genetic variant. \[...\] As such, alignment errors are unlikely to be driving the detection of trans-genome eQTLs for mitochondrial encoded gene expression."

We also detail our approach in the Materials and methods section as follows:

"NUMT sequences were obtained from the UCSC genome browser track named 'numtS', and were generated by Simone et al., 2011, who used blastN to map nuclear chromosomes to the mitochondrial genome, setting the e-value threshold to 0.001. \[...\] For each nuclear genetic variant associated with a mitochondrial encoded gene, we then tested whether any of the 50bp k-mers from the mitochondrial encoded gene aligned within a nuclear gene whose transcription start site fell within 1MB of the corresponding nuclear genetic variant."

> 4\) It is necessary to address questions regarding ancestry and linkage disequilibrium, particularly considering diverse ancestries represented in the RNA-seq data and potential differences with those in the GWAS data used. The manuscript evaluates SNPs in NHGRI GWAS catalogue in strong LD with the SNPs that control mtDNA gene expression. What LD reference is used? Is it the European LD reference calculated from 1000 genomes, or is it the in-sample LD from the datasets with RNAseq data? What were the populations (ancestries) in which the GWAS was performed? In other words, is the LD between SNPs calibrated for the GWAS or for the eQTL analyses? While it may not be possible to match LD perfectly between GWAS and eQTL analyses, these potential issues should be mentioned and some attempt made to determine if they are problematic. If the individual data is available, it is necessary to discuss single/per population analysis to show that their results are real and not artifacts of population structure and also likely consistent across populations. This would involve simply sectioning out the samples from each single population, and rerunning their analysis. The associations are not expected to be significant in the single population analysis since they\'ll have much smaller sample sizes, but the effect sizes and directions should be correlated. If this is not possible, then caveats of population structure need to be mentioned and the claims toned down accordingly.

Linkage disequilibrium values were calculated within the samples used to detect mitochondrial trans-genome eQTLs. This is now made clearer in the Materials and methods section:

"In order to identify whether genetic variants associated with mitochondrial encoded gene expression may play a role in complex disease, we first identified any SNP in linkage disequilibrium (r^2^\>0.8, calculated using datasets and samples used in this study) with peak eQTL SNPs in any of the datasets used for the tissue type in which the association was identified."

For GWAS variants that are in LD with variants associated with mitochondrial encoded gene expression, GWAS were conducted using individuals of Finnish (systolic blood pressure), European (diastolic -- newly described) and European (Vitiligo) descent, whereas our eQTL analysis included individuals from diverse ancestries (although mostly of European descent). In order to try to match LD patterns more closely between our analyses and those conducted within GWAS, we repeated our analyses for the relevant genetic variants in whole blood data using only individuals of European descent. To do this we plotted the first two genetic principal components from samples in our study against those derived from 1000 genomes samples with known ancestry for any dataset that had associated RNA sequencing data from whole blood. We then selected samples that clustered with Europeans in 1000 genomes data by visual inspection and re-ran association analyses as before for whole blood data from CARTaGENE, TwinsUK and GTEx, before performing meta-analysis to calculate P-values. In all cases we find that the associations involving genetic variants in LD with GWAS variants remain highly significant. We also note that overlapping mitochondrial-encoded eQTL and GWAS variants are in strong LD in combined European populations surveyed by the 1000 Genomes project (r^2^\>0.8 in all cases). These results imply that genetic variants associated with mitochondrial encoded gene expression are genuinely in LD with GWAS signals, however we agree that some caution should still be applied if populations within Europe are likely to generate further substructure in the data, which we have limited power to disentangle here. We now document this new analysis, together with a discussion of further population substructure, in the results section as follows:

"Genome-wide association studies considering blood pressure were conducted in individuals of Finnish (Kristiansson et al., 2012) and European descent (Ehret et al., 2016), and the study of Vitiligo was also conducted using individuals of European descent (Jin et al., 2016). \[...\] These results imply that genetic variants associated with mitochondrial encoded gene expression are genuinely in LD with GWAS signals, however some caution should still be applied if populations within Europe are likely to generate further substructure in the data, which we have limited power to disentangle here."

As well as in the Materials and methods section as follows:

"To test whether associations between nuclear genetic variants and mitochondrial encoded gene expression that overlap GWAS signals are significant in individuals of European descent, we plotted the first two genetic principal components against those derived from 1000 genomes samples with known ancestry for any dataset that had associated RNA sequencing data from whole blood. We then selected samples that clustered with Europeans in 1000 genomes data by visual inspection and re-ran association analyses as before for whole blood data from CARTaGENE, TwinsUK and GTEx, before performing meta-analysis to calculate P-values."
